98%
921
2 minutes
20
Manipulating CD28 co-stimulation is a key element of anti-tumour immune responses and treating autoimmune diseases. CD28 can reduce the T cell activation threshold but has a complex relationship with T cell receptor (TCR) signalling and an unclear role in specific T cell subsets. Using a series of stimulation assays, we have studied the relative contribution of CD28 and TCR signals in human CD4 + T cell responses. We show that not only the quantity of CD28 co-stimulation but also its intensity relative to TCR differentially impacts the division of naïve and memory T cells. We show that CD28 co-stimulation can have TCR-independent effects on memory T cell phenotype and cytokine production and in some settings can antagonize TCR-driven functions. These data highlight the complex relationship between CD28 co-stimulation and TCR signals and expose clear differences in their use by naïve and memory T cells.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150779 | PMC |
http://dx.doi.org/10.1093/discim/kyaf006 | DOI Listing |
Eur J Immunol
September 2025
Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.
Memory T cells, a sizable compartment of the mature immune system, enable enhanced responses upon re-infection with the same pathogen. We have recently shown that virus-experienced innate acting T (T) cells can modulate infectious or autoimmune diseases through TCR-independent IFN-γ production. However, how these cells arise remains unclear.
View Article and Find Full Text PDFFront Immunol
September 2025
Department of Experimental Pediatrics, University Hospital, Otto-von-Guericke-University, Magdeburg, Germany.
Tumors frequently evade immune destruction by impairing cytotoxic CD8 T-cell responses, highlighting the need for strategies that restore T-cell functionality. Here, we identify SLAMF7 (CD319) as a key enhancer of human CD8 T-cell responses against tumors. SLAMF7 expression is induced by pro-inflammatory signals such as IL-12 and CD28 co-stimulation.
View Article and Find Full Text PDFBMC Nephrol
August 2025
Department of Internal Medicine, King Khalid University College of Medicine, Abha, Saudi Arabia.
Non-melanoma skin cancer is a prevalent complication in renal transplant recipients due to long-term immunosuppressive therapy. Calcineurin inhibitors, such as tacrolimus and cyclosporine, are effective in preventing graft rejection; however, they significantly increase the risk of non-melanoma skin cancer through broad immunosuppressive and pro-oncogenic mechanisms. Belatacept, a selective co-stimulation blocker targeting the CD80/CD86-CD28 axis, has emerged as a mechanistically distinct alternative with potential benefits for oncologic and renal outcomes.
View Article and Find Full Text PDFAIDS Res Hum Retroviruses
August 2025
Department of Immunology and Microbiology, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, Florida, USA.
Adeno-associated virus (AAV)-vectored delivery of HIV-1 broadly neutralizing antibodies (bNAbs) holds promise for achieving durable HIV-1 immunity in a practical and scalable way, yet AAV-encoded bNAbs often elicit antidrug antibody (ADA) responses that limit transgene expression. Engagement of T cell-expressed CD28 with its ligands CD80/CD86 on professional antigen-presenting cells is crucial for initiating adaptive immunity. Because the immunoglobulin-fusion protein CTLA4Ig can outcompete CD28 for binding to CD80/CD86, CTLA4Ig can inhibit T cell activation and prevent immune responses.
View Article and Find Full Text PDFMol Ther
August 2025
Department of Microbiology, Perelman School ofMedicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Center for Cellular Immunotherapies, Perelman School ofMedicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Institute for Immunology and Immune Health, Perelman School of
We explore whether T cells expressing two chimeric antigen receptors (CARs) with distinct signaling motifs (dual CARs) improve CART cell (CART) efficacy against leukemia and lymphoma. Moreover, we investigate whether dual CARTs targeting two antigens (multi-targeted) are superior to dual CARTs targeting a single antigen (single targeted). Functional assays revealed that multi-targeted dual CARTs targeting both CD19 and CD22 were more potent than single-targeted dual CARTs targeting only CD19 or CD22.
View Article and Find Full Text PDF